Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health care and social assistance entities : Viridian therapeutics inc save search
SHCO INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Soho House & Co. Inc. (NYSE: SHCO) and Encourages Investors to Contact the Firm
Published: 2024-03-29 (Crawled : 13:00) - prnewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
house
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 17:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -0.94%
H: 1.8%
C: -4.03%
conference biopharma global therapeutics
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 00:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 1.09%
H: 2.57%
C: 0.67%
year therapeutics financial results
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
Published: 2024-01-18 (Crawled : 09:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -3.59%
H: 0.0%
C: -6.37%
offering therapeutics
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
Published: 2024-01-08 (Crawled : 14:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -0.8%
H: 9.79%
C: 8.65%
conference key therapeutics
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.19%
H: 3.53%
C: 2.09%
conference presentation therapeutics
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
Published: 2023-12-18 (Crawled : 13:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 1.04%
H: 11.12%
C: 8.39%
vrdn-003 disease positive thyroid eye program therapeutics potential study
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -0.68%
H: 3.3%
C: -2.36%
conference therapeutics
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
Published: 2023-11-08 (Crawled : 15:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.54%
H: 0.37%
C: -5.06%
conference therapeutics
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
Published: 2023-11-03 (Crawled : 22:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 2.98%
H: 9.45%
C: 4.76%
meeting therapeutics
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 2.99%
H: 9.88%
C: 2.12%
therapeutics
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.77%
H: 8.93%
C: 7.74%
drug device disease thyroid eye therapeutics agreement
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
Published: 2023-09-25 (Crawled : 13:00) - biospace.com/
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.84%
H: 1.69%
C: -1.47%
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: -0.24%
H: 1.31%
C: -0.25%
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -3.7%
H: 5.46%
C: 2.59%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
update therapeutics financial results
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
Published: 2023-05-08 (Crawled : 12:00) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.27%
H: 0.13%
C: -3.34%
partnership drug therapeutics
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-05-04 (Crawled : 20:00) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 1.2%
H: 0.79%
C: -5.33%
nasdaq grants therapeutics
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
Published: 2023-05-02 (Crawled : 12:00) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -0.42%
H: 1.65%
C: -2.21%
update therapeutics financial
Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
Published: 2022-03-14 (Crawled : 14:20) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.25%
H: 1.7%
C: -1.68%
conference therapeutics
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: 0.75%
H: 6.59%
C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics
Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
Published: 2022-04-04 (Crawled : 14:20) - globenewswire.com
VRDN | $14.23 -0.49% -0.49% 540K
|
Health Care and Social Assistan...
|
| O: -0.79%
H: 7.54%
C: 0.75%
HTGC 4 | $18.85 0.86% 0.26% 900K
|
Finance
|
| O: -0.16%
H: 1.29%
C: 0.71%
therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.